Rani Therapeutics Holdings, Inc. reported its financial results for the first quarter of 2026, revealing a contract revenue of $1.7 million, a significant increase from $172,000 in the same period last year. This revenue primarily stems from the company's collaboration with Chugai Pharmaceutical Co., Ltd., which was formalized in October 2025. The company’s total operating expenses decreased to $10.0 million from $12.2 million year-over-year, driven by reductions in both research and development costs and general and administrative expenses. The net loss for the quarter was $8.0 million, a 37.1% improvement compared to a net loss of $12.7 million in the prior year.
In terms of operational metrics, Rani Therapeutics has made notable progress in its clinical development. The company is advancing its RaniPill capsule technology, which aims to provide an oral delivery method for biologics. The RaniPill HC, a high-capacity version of the capsule, is currently undergoing a Phase 1 clinical trial for the treatment of obesity in collaboration with ProGen Co., Ltd. This trial is expected to evaluate the safety and efficacy of the RaniPill HC capsule containing a bispecific GLP-1/GLP-2 receptor agonist.
The company’s financial position has also changed, with cash and cash equivalents decreasing to $9.6 million as of March 31, 2026, down from $18.6 million at the end of 2025. Marketable securities increased to $33.8 million, contributing to total current assets of $47.1 million. Rani Therapeutics reported an accumulated deficit of $139.6 million, reflecting ongoing investments in research and development. The company anticipates that its existing cash and marketable securities will be sufficient to fund operations for at least the next twelve months.
Looking ahead, Rani Therapeutics plans to continue its focus on advancing the RaniPill technology and expanding its clinical trials. The company is actively seeking additional funding through equity offerings, collaborations, and other financing arrangements to support its development pipeline. However, it acknowledges the inherent risks and uncertainties associated with clinical development and market conditions that could impact its ability to raise capital and achieve profitability. The company remains committed to its strategic partnerships and aims to leverage its technology platform to enhance its product offerings in the biotherapeutics market.
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics develops oral biotherapeutic delivery platforms, primarily the RaniPill capsule, to administer biologics such as antibodies, peptides, and proteins. Its technology aims to replace injections with convenient oral dosing, targeting markets like obesity, inflammatory diseases, and osteoporosis. The company collaborates with biopharma partners, advancing a pipeline of clinical and preclinical biologic candidates with high bioavailability and precision delivery.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.